316 related articles for article (PubMed ID: 35378329)
21. Hepatic Krüppel-like factor 16 (KLF16) targets PPARα to improve steatohepatitis and insulin resistance.
Sun N; Shen C; Zhang L; Wu X; Yu Y; Yang X; Yang C; Zhong C; Gao Z; Miao W; Yang Z; Gao W; Hu L; Williams K; Liu C; Chang Y; Gao Y
Gut; 2021 Nov; 70(11):2183-2195. PubMed ID: 33257471
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease.
Majdi A; Aoudjehane L; Ratziu V; Islam T; Afonso MB; Conti F; Mestiri T; Lagouge M; Foufelle F; Ballenghien F; Ledent T; Moldes M; Cadoret A; Fouassier L; Delaunay JL; Aït-Slimane T; Courtois G; Fève B; Scatton O; Prip-Buus C; Rodrigues CMP; Housset C; Gautheron J
J Hepatol; 2020 Apr; 72(4):627-635. PubMed ID: 31760070
[TBL] [Abstract][Full Text] [Related]
23. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
[TBL] [Abstract][Full Text] [Related]
24. Necroptosis is a key pathogenic event in human and experimental murine models of non-alcoholic steatohepatitis.
Afonso MB; Rodrigues PM; Carvalho T; Caridade M; Borralho P; Cortez-Pinto H; Castro RE; Rodrigues CM
Clin Sci (Lond); 2015 Oct; 129(8):721-39. PubMed ID: 26201023
[TBL] [Abstract][Full Text] [Related]
25. Inhibiting Interleukin 11 Signaling Reduces Hepatocyte Death and Liver Fibrosis, Inflammation, and Steatosis in Mouse Models of Nonalcoholic Steatohepatitis.
Widjaja AA; Singh BK; Adami E; Viswanathan S; Dong J; D'Agostino GA; Ng B; Lim WW; Tan J; Paleja BS; Tripathi M; Lim SY; Shekeran SG; Chothani SP; Rabes A; Sombetzki M; Bruinstroop E; Min LP; Sinha RA; Albani S; Yen PM; Schafer S; Cook SA
Gastroenterology; 2019 Sep; 157(3):777-792.e14. PubMed ID: 31078624
[TBL] [Abstract][Full Text] [Related]
26. Hepatic Notch1 deletion predisposes to diabetes and steatosis via glucose-6-phosphatase and perilipin-5 upregulation.
Bernsmeier C; Dill MT; Provenzano A; Makowska Z; Krol I; Muscogiuri G; Semela D; Tornillo L; Marra F; Heim MH; Duong FH
Lab Invest; 2016 Sep; 96(9):972-80. PubMed ID: 27428080
[TBL] [Abstract][Full Text] [Related]
27. Vitamin D receptor targets hepatocyte nuclear factor 4α and mediates protective effects of vitamin D in nonalcoholic fatty liver disease.
Zhang H; Shen Z; Lin Y; Zhang J; Zhang Y; Liu P; Zeng H; Yu M; Chen X; Ning L; Mao X; Cen L; Yu C; Xu C
J Biol Chem; 2020 Mar; 295(12):3891-3905. PubMed ID: 32051143
[TBL] [Abstract][Full Text] [Related]
28. Control of diabetic hyperglycaemia and insulin resistance through TSC22D4.
Ekim Üstünel B; Friedrich K; Maida A; Wang X; Krones-Herzig A; Seibert O; Sommerfeld A; Jones A; Sijmonsma TP; Sticht C; Gretz N; Fleming T; Nawroth PP; Stremmel W; Rose AJ; Berriel-Diaz M; Blüher M; Herzig S
Nat Commun; 2016 Nov; 7():13267. PubMed ID: 27827363
[TBL] [Abstract][Full Text] [Related]
29. Hepatocyte MyD88 affects bile acids, gut microbiota and metabolome contributing to regulate glucose and lipid metabolism.
Duparc T; Plovier H; Marrachelli VG; Van Hul M; Essaghir A; Ståhlman M; Matamoros S; Geurts L; Pardo-Tendero MM; Druart C; Delzenne NM; Demoulin JB; van der Merwe SW; van Pelt J; Bäckhed F; Monleon D; Everard A; Cani PD
Gut; 2017 Apr; 66(4):620-632. PubMed ID: 27196572
[TBL] [Abstract][Full Text] [Related]
30. miR-873-5p targets mitochondrial GNMT-Complex II interface contributing to non-alcoholic fatty liver disease.
Fernández-Tussy P; Fernández-Ramos D; Lopitz-Otsoa F; Simón J; Barbier-Torres L; Gomez-Santos B; Nuñez-Garcia M; Azkargorta M; Gutiérrez-de Juan V; Serrano-Macia M; Rodríguez-Agudo R; Iruzubieta P; Anguita J; Castro RE; Champagne D; Rincón M; Elortza F; Arslanow A; Krawczyk M; Lammert F; Kirchmeyer M; Behrmann I; Crespo J; Lu SC; Mato JM; Varela-Rey M; Aspichueta P; Delgado TC; Martínez-Chantar ML
Mol Metab; 2019 Nov; 29():40-54. PubMed ID: 31668391
[TBL] [Abstract][Full Text] [Related]
31. Hepatocyte HIF-1 and Intermittent Hypoxia Independently Impact Liver Fibrosis in Murine Nonalcoholic Fatty Liver Disease.
Mesarwi OA; Moya EA; Zhen X; Gautane M; Zhao H; Wegbrans Giró P; Alshebli M; McCarley KE; Breen EC; Malhotra A
Am J Respir Cell Mol Biol; 2021 Oct; 65(4):390-402. PubMed ID: 34003729
[TBL] [Abstract][Full Text] [Related]
32. Ketohexokinase inhibition improves NASH by reducing fructose-induced steatosis and fibrogenesis.
Shepherd EL; Saborano R; Northall E; Matsuda K; Ogino H; Yashiro H; Pickens J; Feaver RE; Cole BK; Hoang SA; Lawson MJ; Olson M; Figler RA; Reardon JE; Nishigaki N; Wamhoff BR; Günther UL; Hirschfield G; Erion DM; Lalor PF
JHEP Rep; 2021 Apr; 3(2):100217. PubMed ID: 33490936
[TBL] [Abstract][Full Text] [Related]
33. CCN1 promotes hepatic steatosis and inflammation in non-alcoholic steatohepatitis.
Ju L; Sun Y; Xue H; Chen L; Gu C; Shao J; Lu R; Luo X; Wei J; Ma X; Bian Z
Sci Rep; 2020 Feb; 10(1):3201. PubMed ID: 32081971
[TBL] [Abstract][Full Text] [Related]
34. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis.
Yamaguchi K; Yang L; McCall S; Huang J; Yu XX; Pandey SK; Bhanot S; Monia BP; Li YX; Diehl AM
Hepatology; 2007 Jun; 45(6):1366-74. PubMed ID: 17476695
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of PU.1 ameliorates metabolic dysfunction and non-alcoholic steatohepatitis.
Liu Q; Yu J; Wang L; Tang Y; Zhou Q; Ji S; Wang Y; Santos L; Haeusler RA; Que J; Rajbhandari P; Lei X; Valenti L; Pajvani UB; Qin J; Qiang L
J Hepatol; 2020 Aug; 73(2):361-370. PubMed ID: 32135178
[TBL] [Abstract][Full Text] [Related]
36. Proteomic analysis reveals exercise training induced remodelling of hepatokine secretion and uncovers syndecan-4 as a regulator of hepatic lipid metabolism.
De Nardo W; Miotto PM; Bayliss J; Nie S; Keenan SN; Montgomery MK; Watt MJ
Mol Metab; 2022 Jun; 60():101491. PubMed ID: 35381388
[TBL] [Abstract][Full Text] [Related]
37. Non-Alcoholic Fatty Liver Disease.
Engin A
Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
[TBL] [Abstract][Full Text] [Related]
38. Thrombospondin 1 improves hepatic steatosis in diet-induced insulin-resistant mice and is associated with hepatic fat content in humans.
Bai J; Xia M; Xue Y; Ma F; Cui A; Sun Y; Han Y; Xu X; Zhang F; Hu Z; Liu Z; Liu Y; Cai G; Su W; Sun X; Wu H; Yan H; Chang X; Hu X; Bian H; Xia P; Gao J; Li Y; Gao X
EBioMedicine; 2020 Jul; 57():102849. PubMed ID: 32580141
[TBL] [Abstract][Full Text] [Related]
39. Roux-en-y gastric bypass attenuates hepatic mitochondrial dysfunction in mice with non-alcoholic steatohepatitis.
Verbeek J; Lannoo M; Pirinen E; Ryu D; Spincemaille P; Vander Elst I; Windmolders P; Thevissen K; Cammue BP; van Pelt J; Fransis S; Van Eyken P; Ceuterick-De Groote C; Van Veldhoven PP; Bedossa P; Nevens F; Auwerx J; Cassiman D
Gut; 2015 Apr; 64(4):673-83. PubMed ID: 24917551
[TBL] [Abstract][Full Text] [Related]
40. CerS5 deficiency promotes liver fibrosis development in non-alcoholic fatty liver disease.
Chen J; Hao Y; Xu P; Bian D; Han L; Wu X; Zhuang Z; Wang J; Luo Y
Biochem Biophys Res Commun; 2023 Jul; 667():120-126. PubMed ID: 37216827
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
